Jump to content

FDA notification on Iressa

By chumma
December 18, 2004 in NSCLC GROUP

Share

Recommended Posts

Iressa failed to show survival advantage in a large clinical trial. You may read the FDA notification regarding this issue at

Tarceva, taxotere and alimta are still options in this setting

Regards

Betsy

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

× Pasted as rich text. Restore formatting

Only 75 emoji are allowed.

× Your link has been automatically embedded. Display as a link instead

× Your previous content has been restored. Clear editor

× You cannot paste images directly. Upload or insert images from URL.

×

Share

×

×

By using this site, you agree to our Terms of Use.

I accept